Abivax SA’s Successful Capital Raise and Market Surge
In a remarkable week for the French biotechnology company Abivax SA, the firm has successfully raised significant capital and witnessed a dramatic surge in its stock price. On July 25, 2025, Abivax announced the full exercise of underwriters’ options to purchase additional American Depositary Shares (ADSs), bringing the gross proceeds of the offering to $747.5 million (€637.5 million). This capital raise was facilitated through the placement of 10,156,000 ADSs, with underwriters exercising their option to acquire an additional 1,523,400 ADSs, totaling 11,679,400 ADSs at $64.00 per ADS.
The capital raise was part of a broader strategy to fund the development of Abivax’s promising pipeline of therapeutics. The company, which specializes in anti-viral therapies and therapeutic vaccines, has been focusing on treatments for infectious diseases prevalent in Asia and Latin America. Key products in its pipeline include ABX 464, a candidate for HIV/AIDS treatment in Phase II clinical trials, and ABX 203, a therapeutic vaccine for chronic hepatitis B in Phase IIb/III trials.
The capital raise was significantly bolstered by positive Phase-3 data for Obefazimod, Abivax’s leading candidate for treating Colitis Ulcerosa (UC). The announcement of these promising results led to a staggering 586% increase in Abivax’s stock price within a single trading day on the Nasdaq, highlighting the market’s strong response to the company’s clinical advancements.
Abivax’s successful capital raise and stock performance have been widely covered in financial news. Reports from sources such as Le Figaro and Les Echos highlighted the company’s “success-story” narrative, emphasizing the strategic capital raise and the market’s enthusiastic reception. The company’s ability to exceed its fundraising expectations by over $650 million underscores its strong market position and investor confidence.
With a market capitalization of €3.7 billion and a close price of €57 as of July 24, 2025, Abivax continues to be a significant player in the biotechnology sector. The company’s strategic partnerships and collaborations, including those with the French National Centre for Scientific Research and the Cuban Centro de Ingenia Genetica y de Biotecnologia, further strengthen its research and development capabilities.
As Abivax moves forward, the capital raised will be instrumental in advancing its clinical programs and expanding its therapeutic portfolio, positioning the company as a leader in the development of innovative treatments for chronic inflammatory and infectious diseases.